1/4
The lack of pumping from #AVCT following today's #SKIN update and indeed ever since this particular potential revenue stream was first published (13th July), along with their respect that this is a Integumen show, is worthy of note.
The lack of pumping from #AVCT following today's #SKIN update and indeed ever since this particular potential revenue stream was first published (13th July), along with their respect that this is a Integumen show, is worthy of note.
2/4
As AVCT stated today ;
"Once detailed validation of the sensors has been carried out using SARS-COV-2 virus samples at the University of Aberdeen, and we have reviewed those data, Avacta will provide a further update to the market."
As AVCT stated today ;
"Once detailed validation of the sensors has been carried out using SARS-COV-2 virus samples at the University of Aberdeen, and we have reviewed those data, Avacta will provide a further update to the market."
3/4
So its again about having independent verified clinical data (not internal), before likely going into a full commercial agreement and then telling the market all about it.
That resonates once again with the approach to both the BAMS and LFT programmes.
So its again about having independent verified clinical data (not internal), before likely going into a full commercial agreement and then telling the market all about it.
That resonates once again with the approach to both the BAMS and LFT programmes.
4/4
It also demonstrates that the short term performance of the SP, isn't what is king here. Its about progress and professionalism.
These sorts of tells are important to us investors, in deciding who to back, who to trust and who to be patient with.
It also demonstrates that the short term performance of the SP, isn't what is king here. Its about progress and professionalism.
These sorts of tells are important to us investors, in deciding who to back, who to trust and who to be patient with.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
